Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-172M | $-166M | $-113M | -212.2% | - | 105.5% |
| 2024 | $0M | $-91M | $-81M | $-71M | -46.9% | - | 118.1% |
| 2023 | $0M | $-41M | $-37M | $-34M | -45.2% | - | 4.5% |
| 2022 | $0M | $-36M | $-35M | $-28M | -31.9% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 172.50 |
| Research And Development | 154.22 |
| Selling General And Administration | 18.27 |
| Total Expenses | 172.50 |
| Operating Income | -172.50 |
| Total Operating Income As Reported | -172.50 |
| EBITDA | -172.15 |
| Normalized EBITDA | -172.15 |
| EBIT | -172.50 |
| Other Non Operating Income Expenses | 6.82 |
| Other Income Expense | 6.82 |
| Pretax Income | -165.67 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -165.67 |
| Net Income From Continuing And Discontinued Operation | -165.67 |
| Net Income From Continuing Operation Net Minority Interest | -165.67 |
| Net Income | -165.67 |
| Net Income Common Stockholders | -165.67 |
| Net Income Including Noncontrolling Interests | -165.67 |
| Normalized Income | -165.67 |
| Diluted NI Availto Com Stockholders | -165.67 |
| Basic Average Shares | 72.95 |
| Diluted Average Shares | 72.95 |
| Reconciled Depreciation | 0.35 |
| General And Administrative Expense | 18.27 |
| Other Gand A | 18.27 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc.this co. | LRMR | $342M | - | 4.38 | -212.2% | - |
| Atea Pharmaceuticals, Inc. | AVIR | $354M | -2.23 | 1.28 | -57.5% | -1.43 |
| Greenwich LifeSciences, Inc. | GLSI | $347M | -21.99 | 136.99 | -623.1% | - |
| Enanta Pharmaceuticals, Inc. | ENTA | $341M | -4.17 | 5.27 | -126.5% | -5.14 |
| Verastem, Inc. | VSTM |
| - |
| - |
| - |
| - |
| $339M |
| -1.62 |
| 5.93 |
| -366.2% |
| -1.07 |
| Simulations Plus, Inc. | SLP | $336M | -5.20 | 2.70 | -51.9% | 20.82 |
| 908 Devices Inc. | MASS | $334M | 17.11 | 2.32 | 13.6% | -12.61 |
| Abeona Therapeutics Inc. | ABEO | $332M | 4.66 | 2.08 | 44.7% | 3.54 |
| Humacyte, Inc. | HUMA | $331M | -8.10 | 106.40 | -1313.4% | -15.52 |
| Peer Median | - | -3.20 | 3.98 | -92.0% | -1.43 | |